Completed PHASE3 INTERVENTIONAL 2-arm NCT01730534

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Sponsor: AstraZeneca

Conditions Diabetes Mellitus, Non-Insulin-Dependent High Risk for Cardiovascular Event

Interventions Dapagliflozin 10 mg Placebo tablet

Updated 17 times since 2017 Last updated: Dec 11, 2019 Started: Apr 25, 2013 Primary completion: Sep 11, 2018 Completion: Sep 11, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01730534, this PHASE3 trial focuses on Diabetes Mellitus, Non-Insulin-Dependent and High Risk for Cardiovascular Event and remains completed. Sponsored by AstraZeneca, it has been updated 17 times since 2013, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

17 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 12 earlier versions

Jan 2020 — Jan 2021 [monthly]

Completed PHASE3
Nov 2018 — Jan 2020 [monthly]

Completed PHASE3
Oct 2018 — Nov 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jul 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2018 — Apr 2018 [monthly]

Active Not Recruiting PHASE3
Oct 2017 — Jan 2018 [monthly]

Active Not Recruiting PHASE3
Jul 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Apr 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Apr 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Bristol-Myers Squibb
Hadassah Medical Organization
The TIMI Study Group

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Acapulco, Mexico , Addlestone, United Kingdom , Adelaide - Oaklands Park, Australia , Afula, Israel , Ahmedabad, India , Alberton, South Africa , Albuquerque, United States , Alexander City, United States , Alexandria, United States and 628 more locations